4//SEC Filing
Shah Prem S 4
Accession 0001127602-22-022028
CIK 0000064803other
Filed
Sep 1, 8:00 PM ET
Accepted
Sep 2, 4:47 PM ET
Size
20.3 KB
Accession
0001127602-22-022028
Insider Transaction Report
Form 4
Shah Prem S
EVP and Group President
Transactions
- Award
Common Stock (RSU)
2022-08-31+20,376→ 20,376 total
Holdings
- 11,259.195
Phantom Stock Credits
Exercise: $1.00→ Common Stock (11,259.195 underlying) - 43,453.24
Common Stock
- 4,538.888
ESOP Common Stock
- 2,829
Common Stock (restricted)
- 6,671.959
Stock Unit (deferred)
- 2,935
Stock Option
Exercise: $104.82From: 2017-04-01Exp: 2023-04-01→ Common Stock (2,935 underlying) - 28,596
Stock Option
Exercise: $58.34From: 2021-04-01Exp: 2030-04-01→ Common Stock (28,596 underlying) - 41,580
Stock Option
Exercise: $101.09From: 2023-04-01Exp: 2032-04-01→ Common Stock (41,580 underlying) - 4,438.154
Common Stock (pep)
- 16,522
Common Stock (restricted)
- 9,469
Stock Option
Exercise: $54.19From: 2020-04-01Exp: 2029-04-01→ Common Stock (9,469 underlying) - 846
Stock Option
Exercise: $62.21From: 2019-04-01Exp: 2025-04-01→ Common Stock (846 underlying) - 28,723
Stock Option
Exercise: $74.30From: 2022-04-01Exp: 2031-04-01→ Common Stock (28,723 underlying) - 26,580
Stock Option
Exercise: $75.24From: 2021-08-31Exp: 2028-08-31→ Common Stock (26,580 underlying)
Footnotes (13)
- [F1]Consists of RSUs awarded pursuant to the Issuer's 2017 Stock Incentive Plan. Restrictions lapse on the third anniversary of the grant date.
- [F10]Option becomes exercisable in four equal installments, commencing 4/1/2023.
- [F11]Option vests in three equal installments, on 8/31/2021, 8/31/2022 and 8/31/2023.
- [F12]Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- [F13]Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- [F2]Consists of Matching RSUs awarded pursuant to Issuer's Partnership Equity Program, a sub-plan under its ICP, and dividend equivalents on the Matching RSUs. Restrictions lapse on the RSUs on 08/31/2023.
- [F3]Consists of RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan under its 2017 Incentive Compensation Plan. Restrictions on the 2018 grant lapse in three equal installments commencing on 02/26/2022; restrictions on the 2020 grant lapse in two equal installments commencing on 2/28/22.
- [F4]Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
- [F5]Option became exercisable in four equal installments commencing 04/01/2017.
- [F6]Option became exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
- [F7]Option becomes exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised.
- [F8]Option becomes exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
- [F9]Option became exercisable in three equal installments commencing 04/01/2022.
Documents
Issuer
CVS HEALTH Corp
CIK 0000064803
Entity typeother
Related Parties
1- filerCIK 0001900910
Filing Metadata
- Form type
- 4
- Filed
- Sep 1, 8:00 PM ET
- Accepted
- Sep 2, 4:47 PM ET
- Size
- 20.3 KB